Pharmacological interventions for acute major depression and bipolar depression with mixed features: A systematic review and dose-related network meta-analysis across different age groups
In brief
Lurasidone reduced depressive symptoms in mixed bipolar depression at 60 to 80 mg
A network meta-analysis of 35 trials found lurasidone at 60 or 80 mg reduced depressive symptoms versus placebo in adults with mixed bipolar depression, while 60 and 80 mg also outperformed placebo in children and adolescents. Several drugs improved response rates, but larger estimated benefits tended to come from lower-quality studies, so confidence in the comparisons remains limited.
- Journal
- Journal of affective disorders (Q1)
- Published
- 30 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Michele Fornaro, Chiara Di Lorenzo, Nicolas Nunez, Balwinder Singh, Marin Veldic, Fabio Sambataro, et al.
- PMID
- 42815730
- DOI
- 10.1016/j.jad.2026.122568
Why clinicians should know about it
- Picked for Pharmacology (medical) (top studies of the week, 4 October 2026): Systematic review and dose‑related NMA of depression treatments
- Picked for Psychiatry and Mental Health (top studies of the week, 4 October 2026): Network meta‑analysis of mixed depression/bipolar pharmacotherapy
Abstract
BACKGROUND: Acute mixed bipolar/major depression is relatively frequent, yet quantitative information about its pharmacological management is relatively scant, warranting network meta-analysis (NMA) of comparative efficacy/response/acceptability of pharmacological interventions accounting for dose effects across different age groups. METHODS: We searched PubMed/MEDLINE/Embase/Web of Science/Scopus (from database inception to 2026.05.25) for randomized controlled trials (RCTs) comparing pharmacological interventions with each other or placebo in patients with acute major depression/bipolar depression with mixed features. Co-primary outcomes were the change in depressive symptoms and response. Tolerability, acceptability, and change in manic symptoms were secondary outcomes. Confidence-In-Network-Meta-Analysis was appraised. RESULTS: 22 studies assessed 5241 acute mixed bipolar depressed participants, whereas 13 studies encompassed 1852 acute mixed major depression patients. Sensitivity analyses, including those retaining low-risk-of-bias studies only, and excluding outliers for possible effect modifiers, indicated that asenapine-15 mg/day (SMD = -0.54; 95%C.I. = -1.06; -0.02), lurasidone-60 mg/day (SMD = -0.43; 95%C.I. = -0.72, -0.14), lurasidone-80 mg/day (SMD = -0.39; 95%C.I. = -0.55, -0.23) outperformed placebo for depressive symptoms reduction in bipolar patients. Lurasidone-60 mg/day (SMD = -0.43; 95%C.I. = -0.72, -0.14), lurasidone-80 mg/day (SMD = -0.38; 95%C.I. = -0.59, -0.17) outperformed placebo for bipolar children and adolescents. Lurasidone-40 mg/day (SMD = -0.80; 95% C.I. = -0.95, -0.65) outperformed placebo for major depression. Cariprazine-1.5 mg/day (RR = 1.23; 95%C.I. = 1.01, 1.51), cariprazine-3 mg/day (RR = 1.32; 95%C.I. = 1.08, 1.60), lurasidone-80 mg/day (RR = 1.36; 95%C.I. = 1.14, 1.63), olanzapine-12.5 mg/day (RR = 1.63; 95%C.I. = 1.07, 2.51), olanzapine-6 mg/day+fluoxetine-50 mg/day (RR = 2.61; 95%C.I. = 1.60, 4.39) outperformed placebo response in bipolar samples. Lumateperone-42 mg/day (RR = 1.61; 95%C.I. = 1.20; 2.18) outperformed placebo for major depression response. Quetiapine-530 mg/day in augmentation to mood stabilizers led to a significantly higher number of dropouts in bipolar patients than placebo. Meta-regression of the AMSTAR-Plus content score against efficacy and response measures showed that larger effect sizes (SMDs/logRRs) were associated with lower AMSTAR scores, reflecting lower study quality. CONCLUSIONS: Our findings are consistent with previous NMAs and current guidelines, yet they expand knowledge by concurrently appraising different drugs, doses, and age groups, and the quality of the evidence.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.